Secondary prevention with calcium channel-blocking drugs in patients after myocardial infarction: a critical review
Related Experiment Video
Updated: Jul 25, 2026

Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs
Published on: April 17, 2021
Insights
Calcium entry-blocking drugs are evaluated for preventing complications after myocardial infarction. This review compares data from trials of verapamil, nifedipine, and diltiazem to assess their efficacy and safety.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Secondary complications post-myocardial infarction pose significant risks.
- Calcium entry-blocking drugs are a class of medications with potential therapeutic benefits.
Purpose of the Study:
- To present the rationale for evaluating calcium entry-blocking drugs in post-myocardial infarction patients.
- To critically review existing data on verapamil, nifedipine, and diltiazem in this context.
Main Methods:
- Review of postinfarction clinical trial data.
- Comparative analysis of findings from major trials involving specific calcium entry-blocking drugs.
Main Results:
- Data from trials involving verapamil, nifedipine, and diltiazem were critically assessed.
- A comparison of results from three key trials of these drugs was conducted.
Conclusions:
- The review provides a comparative overview of calcium entry-blocking drugs for secondary prevention post-myocardial infarction.
- Efficacy and safety data are synthesized to inform clinical decision-making.
Abstract:
The rationale for evaluating the efficacy and safety of calcium entry-blocking drugs to prevent secondary complications in patients after myocardial infarction is presented. The data currently available from postinfarction trials involving verapamil, nifedipine, and diltiazem are critically reviewed, and a comparison of the findings from three major trials of calcium entry-blocking drugs is provided.
Related Concept Videos
Antihypertensive Drugs: Action of Calcium Channel Blockers
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Antianginal Drugs: Calcium Channel Blockers and Ranolazine
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
Antiepileptic Drugs: Calcium Channel Blockers
Calcium channel blockers exert their antiepileptic effects by targeting T-type calcium channels, which are integral to transmitting nerve signals in the central nervous system. These channels allow the passage of calcium ions, which are vital for neuronal communication. By inhibiting T-type calcium channels, calcium channel blockers effectively reduce the release of neurotransmitters and...
Coronary Artery Disease V: Interprofessional Care

